August 28th 2023
With an increased incidence of this sexually transmitted infection, a review of an older antibiotic for treatment has shown some clinical benefits in other countries.
July 31st 2023
The vaccine has been approved since late 2019 for adults age 18 and older.
July 26th 2023
The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.
The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.
April 7th 2023
When taken within 3 days, doxycycline given post-exposure (doxy-PEP) decreased the incidence rates of syphilis, gonorrhea, and chlamydia significantly.
HPV Immunizations Higher in States Where Adolescents Can Consent to Vaccination
States with policy that permitted adolescents to independently choose to receive HPV vaccination had a significantly higher immunization uptake.
Stemming the Tide: Getting More Providers Involved in PrEP Counseling to Reduce HIV Infections
How 1 provider is training medical peers to offer PrEP education and prescribe it.
Provider Stigma Can Prevent Injection Drug Users from Receiving HIV PrEP
Bias against injection drug users can inhibit them from receiving potentially lifesaving care, such as HIV pre-exposure prophylaxis (PrEP). Community-based responses like syringe service programs help combat this stigma.
Podcasts: An Emerging Communication Medium for Storytelling, Disseminating Health Information
Fenway Health’s Pride in Our Health podcast is an example of new voices being heard, and an alternative means of getting health information to the general public.
HIV Resuppression Outcomes Not Improved with Resistance Testing
Adding genotypic resistance testing (GRT) to routine care did not improve HIV virologic outcomes for patients for whom first-line ART failed, the study authors wrote.
Support for Long-Acting Cabotegravir plus Rilpivirine With or Without Lead-In
Long-acting cabotegravir plus rilpivirine worked with or without a lead-in for ART-naïve HIV patients.
Improving COVID-19 Outcomes in HIV Patients
A new study looks at this population and what factors affect outcomes, including diagnosis. This is significant not only for pandemic response, but also preparedness for vulnerable patient populations.
Lack of Improvement in HIV Infections and Use Prevention Services Among PWID
People who inject drugs (PWID) remain at risk of HIV infection, according to a recent report by the CDC, which found HIV infection and HIV-associated behaviors remained steady between 2015 and 2018.
A Third of New HIV Cases Occurred in “Low-Risk” Gay and Bisexual Men Not Indicated for PrEP
29% of cisgender men who have sex with men acquired HIV despite being designated as “low risk.”
Gilead Announces High Efficacy and Adherence in Biktarvy HIV Treatment Trial
In Gilead’s BICSTaR trial of their full HIV treatment regimen Biktarvy, 97% of treatment-naïve adults and 96% of treatment-experienced adults achieved virological suppression after 1 year.
A Case of Herpes Simplex Virus-2 Encephalitis in the Setting of Pembrolizumab Exposure
Contemporary Issues on the Treatment of Women Living with HIV in the US
The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.
Islatravir: Investigating Long-Term Treatment Options for PrEP
Merck recently announced results looking at their islatravir implant studied for HIV prevention for 3 months. The long-term goal is to have the implant last 12 months following administration.
FDA Approves Expanded Indication for Biktarvy for HIV Treatment in Young Children
Children living with HIV have a new once-daily treatment option to maintain virologic suppression.
HIV Care Disrupted by COVID-19 Pandemic
Comparing 2020 to 2019, investigators saw a reduction in the number of HIV tests, the number of in-person consultations, and new enrollments in care, due to the disruption in HIV care throughout the COVID-19 pandemic.
Predicting PrEP Use Based on PrEP Indications Among MSM
There are MSM who are indicated for PrEP use that don’t use it, and vice versa, the study authors found.
The Promise, Progress of PrEP
This promising class of therapy is an expanding treatment option for people who are looking for HIV prevention offerings.
HIV Self-Tests Boost Testing Among MSM
The TakeMeHome program, a public-private partnership to distribute HIV self-test home kits to at-risk populations, is reaching at-risk individuals who weren’t otherwise accessing testing.
Risk Score May Accurately Predict In-Hospital Mortality of HIV-Positive Patients
The HIV In-hospital Mortality Prediction (HIV-IMP) risk score showed good discrimination and calibration and may be useful in guiding clinical decision-making.
Though HIV Deaths are Decreasing, Women and Black Women Still Have Significantly Higher Mortality Rates
A recent study measured premature deaths among people with HIV by sex, race, and HIV risk factor.
HPV Infections During Pregnancy Associated with Greater Risk of Preterm Birth
Pregnant women infected with certain strains of human papillomavirus during pregnancy had a nearly fourfold greater risk of preterm labor.
Perceptions of and Willingness to Start PrEP among People Who Inject Drugs
People who inject drugs are at high-risk for HIV infection, but very few are interested in PrEP prescriptions.
Global HIV Mortality Trends among Children on Antiretroviral Treatment
Mortality rates of children with HIV may be underreported due to lack of patient follow-up and the usage of routine program data.
FDA Grants Priority Review for New Cabotegravir Long-Acting HIV Prevention and Treatment Drug
Cabotegravir has a target date of January 24, 2022 and would become the first long-acting HIV PrEP therapy approved.
England on Track to End HIV Transmission by 2030
England has been meeting and exceeding its HIV diagnosis and treatment goals set by UNAIDS.
HIV and Kenyan Orphans: Those in Institutional Care May Fare Best
Parentless youth living on the streets had the highest rates of HIV and death, but extended-family living situations were not necessarily better than institutional care.
Investigators Granted IND to Begin HIV Therapy Trials
The therapy, known as EBT-101, works by eliminating HIV-infected DNA from the genome.
PrEP: A Tool Against HIV in Africa
To address PrEP implementation in Kenya, a team of researchers evaluated practices and contextual modifications across public HIV clinics.
Antiretroviral Therapy for HIV Not Associated with Higher Risk for Preterm Birth
Antiretroviral therapy for HIV offers a protective outcome against preterm birth for pregnant women with HIV.
A Vehicle for Care, Counseling Out in the Community
The University of Miami (UM) has a community-based mobile clinic that offers PrEP counseling along with other medical services to those who might not otherwise have access to or seek clinical care.
2 Clarke Drive Cranbury, NJ 08512